# GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

Study · id `cardio:ct-nct07617155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07617155](<https://clinicaltrials.gov/study/NCT07617155>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07617155

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 396 participants.

## Technical summary

Registry record NCT07617155. Randomized; quadruple masking; primary purpose prevention. Start 2026-09 (anticipated); primary completion 2028-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 396 participants (planned count; ClinicalTrials.gov record NCT07617155, source copy `cardio:ctgov-nct07617155-2026-06-01`, retrieved 2026-10-31)
- Planned start: 2026-09 (anticipated) (ClinicalTrials.gov record NCT07617155, source copy `cardio:ctgov-nct07617155-2026-06-01`, retrieved 2026-10-31)
- Primary completion: 2028-09 (anticipated) (ClinicalTrials.gov record NCT07617155, source copy `cardio:ctgov-nct07617155-2026-06-01`, retrieved 2026-10-31)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07617155, source copy `cardio:ctgov-nct07617155-2026-06-01`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07617155, source copy `cardio:ctgov-nct07617155-2026-06-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07617155-2026-06-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
- Acronym: RECAP-GLP1
- Condition: Hypertriglyceridemia Induced Acute Pancreatitis
- Condition: Recurrent Acute Pancreatitis
- Condition: Pancreatitis Relapsing
- Condition: Hypertriglyceridemia
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (Normal Saline)
- Lead sponsor: Peking Union Medical College Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Peking Union Medical College Hospital (`cardio:org-peking-union-medical-college-hospital`)

## Provenance

Content hash: cfb0db86195a467855e1fb8d21608dffeb9a7028269af12a65ab1728d0a43c81
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
